Soligenix (DB:DOA) - Aktienkurs, Nachrichten und Analyse

DOA Aktienübersicht

A late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.

Über das Unternehmen

DOA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 75.85%

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 1.5% pro Jahr sinken.

Hat keine nennenswerte Marktkapitalisierung (€9M)

Erzielt weniger als 1 Million USD an Einnahmen ($949K)

Negatives Eigenkapital

+ 3 mehr Risiken

Soligenix, Inc. Wettbewerber

co.don

XTRA:CNW

€6.5m

Epigenomics

XTRA:ECX

€1.3m

Paion

XTRA:PA8

€2.6m

Medigene

XTRA:MDG1

€37.6m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Soligenix
Historical stock prices
Current Share Price	US$5.85
52 Week High	US$14.11
52 Week Low	US$5.58
Beta	1.74
1 Month Change	0%
3 Month Change	-5.11%
1 Year Change	-10.53%
3 Year Change	-73.29%
5 Year Change	-71.94%
Change since IPO	-77.87%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	DOA	DE Biotechs	DE Markt
7D	0%	-2.7%	-3.1%
1Y	-10.5%	-24.2%	-0.5%

Rendite im Vergleich zur Industrie: DOA übertraf die Branche German Biotechs, die im vergangenen Jahr eine Rendite von -36.9 erzielte.

Rendite vs. Markt: DOA hinter dem Markt German zurück, der im vergangenen Jahr eine Rendite von 8.6 erzielte.

Preisvolatilität

Is DOA's price volatile compared to industry and market?
DOA volatility
DOA Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.3%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.2%
10% least volatile stocks in DE Market	2.6%

Stabiler Aktienkurs: DOA hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von DOA im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1987	14	Christopher Schaber	www.soligenix.com

Soligenix, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Soligenix im Vergleich zum Marktanteil des Unternehmens?
DOA grundlegende Statistiken
Marktanteil	€7.89m
Gewinn(TTM)	-€12.59m
Umsatz(TTM)	€865.50k

9.1x

Kurs-Umsatz-Verhältnis

-0.6x

Kurs-Gewinn-Verhältnis

Ist DOA zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
DOA Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$948.91k
Kosten der Einnahmen	US$550.82k
Bruttogewinn	US$398.09k
Sonstige Ausgaben	US$14.20m
Umsatz	-US$13.80m

Zuletzt gemeldete Gewinne

Dec 31, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-1.45
Bruttomarge	41.95%
Nettogewinnspanne	-1,454.12%
Schulden/Eigenkapital-Verhältnis	-400.6%

Wie hat sich DOA auf lange Sicht entwickelt?

Historische Performance und Vergleiche

DOA Aktienübersicht

Belohnungen

Risikoanalyse

Soligenix, Inc. Wettbewerber

XTRA:CNW

€6.5m

XTRA:ECX

€1.3m

XTRA:PA8

€2.6m

XTRA:MDG1

€37.6m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Recent updates

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Second quarter 2022 earnings released: US$0.055 loss per share (vs US$0.047 loss in 2Q 2021)

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.064 loss in 1Q 2021)

Insufficient new directors

No longer forecast to breakeven

Full year 2021 earnings released: US$0.31 loss per share (vs US$0.64 loss in FY 2020)

Soligenix, Inc. Demonstrates Positive Anti-Tumor Efficacy in Multiple Nonclinical Animal Studies

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.088 loss per share (vs US$0.061 loss in 3Q 2020)

Insufficient new directors

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Soligenix, Inc.'s Grundlagenzusammenfassung

9.1x

-0.6x

Erträge &amp; Einnahmen

Erträge & Einnahmen